Abstract

Recent genomic studies have revealed the critical impact of genetic diversity within small population groups in determining the way individuals respond to drugs. One of the biggest challenges is to accurately predict the effect of single nucleotide variants and to get the relevant information that allows for a better functional interpretation of genetic data. Different conformational scenarios upon the changing in amino acid sequences of pharmacologically important proteins might impact their stability and plasticity, which in turn might alter the interaction with the drug. Current sequence-based annotation methods have limited power to access this type of information. Motivated by these calls, we have developed the Structural Workflow for Annotating ADME Targets (SWAAT) that allows for the prediction of the variant effect based on structural properties. SWAAT annotates a panel of 36 ADME genes including 22 out of the 23 clinically important members identified by the PharmVar consortium. The workflow consists of a set of Python codes of which the execution is managed within Nextflow to annotate coding variants based on 37 criteria. SWAAT also includes an auxiliary workflow allowing a versatile use for genes other than ADME members. Our tool also includes a machine learning random forest binary classifier that showed an accuracy of 73%. Moreover, SWAAT outperformed six commonly used sequence-based variant prediction tools (PROVEAN, SIFT, PolyPhen-2, CADD, MetaSVM, and FATHMM) in terms of sensitivity and has comparable specificity. SWAAT is available as an open-source tool.

Highlights

  • Absorption, Distribution, Metabolism, and Excretion (ADME) genes are key players determining the pharmacokinetic properties of a drug

  • We have screened 32 core ADME genes defined by the PharmaADME standards as very important and involved in drug processing with a high level of evidence

  • We screened all the 23 genes characterized by the PharmVar consortium [54]

Read more

Summary

Introduction

Absorption, Distribution, Metabolism, and Excretion (ADME) genes are key players determining the pharmacokinetic properties of a drug. More than 300 genes have been identified to contribute to the ADME properties. The function of 32 core ADME genes has been confirmed by extensive studies [1]. Drug response depends on the variants of the ADME genes found in an individual. Depending on the genetic variability, the well-studied CYP2D6 ADME gene is associated with ultrarapid, intermediate, or poor metabolization of tamoxifen [2]. The polymorphism of ADME genes is a distinctive property of different populations [3,4,5,6]. Clinically actionable variants of ADME genes deviate significantly between Sub-Saharan Africa and other worldwide populations [7]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call